Acetaminophen Toxicity Headed To NDAC, New FDA Drug Safety Group
This article was originally published in The Tan Sheet
Executive Summary
Potential liver toxicity risks from acetaminophen use are likely to be among the topics at the inaugural meeting of FDA's Drug Safety & Risk Management Subcommittee
You may also be interested in...
LipoKinetix Cases Prompt Support For Mandatory Supplement AE Reporting
Seven hepatotoxicity adverse event reports linked to Syntrax' LipoKinetix weight-loss supplement further support the need for mandatory AE reporting for supplement manufacturers, University of Pennsylvania researchers say
LipoKinetix Cases Prompt Support For Mandatory Supplement AE Reporting
Seven hepatotoxicity adverse event reports linked to Syntrax' LipoKinetix weight-loss supplement further support the need for mandatory AE reporting for supplement manufacturers, University of Pennsylvania researchers say
LipoKinetix Cases Prompt Support For Mandatory Supplement AE Reporting
Seven hepatotoxicity adverse event reports linked to Syntrax' LipoKinetix weight-loss supplement further support the need for mandatory AE reporting for supplement manufacturers, University of Pennsylvania researchers say